Neuromeka뉴로메카
348340 · KOSDAQ · ₩348340 · 뉴로메카
₩17,210▼ ₩830 (4.60%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Gross margin | 19.3% | 18.3% | 16.4% | 8.9% | 11.8% |
| Operating margin | −89.5% | −78.4% | −75.2% | −107.9% | −79.9% |
| Net margin | −221.2% | −115.9% | −66.0% | −128.5% | −84.1% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue growth | −4.2% | −25.0% | +83.9% | +40.9% | — |
| Operating income growth | −9.4% | +21.9% | −28.3% | −90.1% | — |
| Net income growth | −82.7% | −31.8% | +5.6% | −115.4% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Return on equity | −159.8% | −177.5% | −95.5% | −55.4% | −20.6% |
| Return on assets | −23.9% | −23.6% | −17.5% | −25.3% | −18.7% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Liabilities to equity | 148.1% | 557.6% | 776.1% | 297.9% | 10.3% |
| Net debt to equity | 100.5% | 97.3% | 311.2% | 61.9% | −20.6% |
| Current ratio | 72.9% | 55.1% | 72.8% | 109.9% | 978.5% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Neuromeka / 뉴로메카 / 348340 / KRX:348340
Source: KRX statistical information